Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 8/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SUV39H2 | Q9H5I1 | 3/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25557392 | 1.00 | CHRNB2 (0.41) | CHRNB2CHRNA4ALKALDH1A1SUV39H2 | |
| SCHEMBL25183447 | 0.94 | CHRNB2 (0.39) | CHRNB2CHRNA4ALKALDH1A1SUV39H2 | |
| SCHEMBL29833756 | 0.94 | CHRNB2 (0.39) | CHRNB2CHRNA4ALKALDH1A1SUV39H2 | |
| SCHEMBL29833741 | 0.77 | AAK1 (0.39) | ALDH1A1 | |
| SCHEMBL13199693 | 0.77 | AAK1 (0.39) | ALDH1A1 | |
| SCHEMBL13199691 | 0.75 | PDPK1 (0.33) | MKNK2 | |
| SCHEMBL4037516 | 0.74 | PDPK1 (0.34) | MKNK2 | |
| SCHEMBL25033150 | 0.74 | INSR (0.32) | ALKMKNK2 | |
| SCHEMBL25183448 | 0.74 | PIK3CG (0.39) | CHRNB2CHRNA4ALKALDH1A1SUV39H2 | |
| SCHEMBL5658561 | 0.74 | CHRNB2 (0.53) | CHRNB2CHRNA4ALKALDH1A1SUV39H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606556-B2 | TYK-2 inhibitor | BEONE MEDICINES I GMBH (CH) | 2026-04-21 | — | — | US | disclosed |
| US-20230159520-A1 | TYK-2 INHIBITOR | BEONE MEDICINES I GMBH (CH) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606556-B2 | TYK-2 inhibitor | TYK2, TXK, JAK1 | CHRNB2 2590/4885CHRNA4 3120/4885ALK 218/4885 |
| US-20230159520-A1 | TYK-2 INHIBITOR | TYK2, IRAK2, PTK2B | CHRNB2 2006/4885CHRNA4 3843/4885ALK 1633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.